ArticleNPJ science of food2025
Polysaccharide from Asimina triloba fruits alleviates DSS-induced ulcerative colitis by modulating inflammatory signaling and gut microbiota.
Article in NPJ science of food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- L-arabinose: a strategic modulator of pathogen virulence for food system safety.Archives of microbiology · 2026Review
- Deep Eutectic Solvent-Based Extraction Optimization, Structural Characterization, and Alleviating Effects ofFoods (Basel, Switzerland) · 2026Article
- The Structure-Decoding-Conversion-Effect Paradigm of Natural Polysaccharides for Gut Microbiota Remodeling in Ulcerative Colitis.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The treatment of ulcerative colitis (UC) remains a clinical challenge due to its frequent recurrence, underscoring the urgent need for novel functional food-based therapeutic strategies. In this study, a polysaccharide (ATP-W-1) was isolated from Asimina triloba fruit, structurally characterized, and evaluated for its therapeutic efficiency in a DSS-induced UC mouse model. ATP-W-1, with a molecular weight of 164,504 g/mol, was composed of mannose, rhamnose, glucose, galactose, and arabinose. In vivo study revealed that ATP-W-1 significantly ameliorated UC symptoms by preventing body weight loss and modulating inflammatory cytokines (IL-6, IL-10, and TNF-α) expression. Specifically, it downregulated IL-6 and TNF-α associated with the NF-κB pathway and restoration of epithelial barrier integrity, as evidenced by increased expression of tight junction proteins (Claudin 1, ZO-1, and Occludin). Furthermore, ATP-W-1 positively modulated the gut microbiota composition and enhanced the prodcution of short-chain fatty acids (SCFAs), thereby contributing to the reestablishment of intestinal homeostasis. Collectively, these findings highlight that ATP-W-1 is a promising functional food ingredient with therapeutic potential for UC prevention and management.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.